Suchergebnisse

Pimecrolimus , a calcineurin inhibitor, is a non-steroidal treatment option in patients aged>= 2 years with mild-to-moderate atopic eczema (AE). It was approved as a viable therapeutic option by the FDA in 2001 and in the European Union a year later in 2002. Calcineurin inhibitors inhibit the synthesis of inflammatory cytokines released from T cells and mast cells. In contrast to corticosteroids, calcineurin inhibitors act specifically on proinflammatory cells. Pimecrolimus shows comparative efficacy to mild topical corticosteroids and a special antipruritic effect. Furthermore, examinations of the systemic absorption of pimecrolimus implicated no systemic immunosuppression. In 2006, the FDA set a black box warning in the packaging materials of pimecrolimus alluding to the risk of skin malignancy or lymphomas due to theoretical consideration.The authors provide a review of pimecrolimus as a treatment for AE. Specifically, the authors present the pharmacokinetic and pharmacodynamic information on pimecrolimus and also review its efficacy. The authors also discuss pimecrolimus' safety and tolerability profile.Pimecrolimus represents a valuable part of active and proactive therapy in AE. That being said, the long-term safety of topical calcineurin inhibitors remains to be investigated. Given the results from experimental photocarcinogenicity studies, effective sun protection should be employed during the therapy, although an increased risk for skin malignancies and lymphomas was not found in recent studies. Pimecrolimus should be considered as an alternative therapeutic approach in AE treatment management going along with a corticoid-sparing effect.

The leading priority for the Polish Presidency of the Council of the European Union was to reduce health inequalities across European societies, and, within its framework, prevention and control of respiratory diseases in children. This very important paper contain proposal of international cooperation on the prevention, early detection and monitoring of asthma and allergic diseases in childhood which will be undertaken by the EU member countries as a result of EU conclusion developed during the Polish Presidency of the Council of the European Union. This will result in collaboration in the field of chronic diseases, particularly respiratory diseases, together with the activity of the network of national institutions and NGOs in this area. Paper also contains extensive analysis of the socio-economic, political, epidemiological, technological and medical factors affecting the prevention and control of childhood asthma and allergy presented during Experts presidential conference organized in Warsaw-Ossa 21–22 September 2011.

Adequate quality is essential for any medicinal product to be eligible for marketing. Quality includes verification of the identity, content and purity of a medicinal product in combination with a specified production process and its control. Allergen products derived from natural sources require particular considerations to ensure adequate quality. Here, we describe key aspects of the documentation on manufacturing and quality aspects for allergen immunotherapy products in the European Union and the United States. In some key parts, requirements in these areas are harmonized while other fields are regulated separately between both regions. Essential differences are found in the use of Reference Preparations, or the requirement to apply standardized assays for potency determination. As the types of products available are different in specific regions, regulatory guidance for such products may also be available in one specific region only, such as for allergoids in the European Union. Region-specific issues and priorities are a result of this. As allergen products derived from natural sources are inherently variable in their qualitative and quantitative composition, these products present special challenges to balance the variability and ensuring batch-to-batch consistency. Advancements in scientific knowledge on specific allergens and their role in allergic disease will consequentially find representation in future regulatory guidelines.

Regulatory approaches for allergen immunotherapy (AIT) products and the availability of high-quality AIT products are inherently linked to each other. While allergen products are available in many countries across the globe, their regulation is very heterogeneous. First, we describe the regulatory systems applicable for AIT products in the European Union (EU) and in the United States (US). For Europe, a depiction of the different types of relevant procedures, as well as the committees involved, is provided and the fundamental role of national agencies of the EU member states in this complex and unique network is highlighted. Furthermore, the regulatory agencies from Australia, Canada, Japan, Russia, and Switzerland provided information on the system implemented in their countries for the regulation of allergen products. While AIT products are commonly classified as biological medicinal products, they are made available by varying types of procedures, most commonly either by obtaining a marketing authorization or by being distributed as named patient products. Exemptions from marketing authorizations in exceptional cases, as well as import of allergen products from other countries, are additional tools applied by countries to ensure availability of needed AIT products. Several challenges for AIT products are apparent from this analysis and will require further consideration.

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon ; Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England ; UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France ; Univ S Florida, Morsani Coll Med, Tampa, FL USA ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland ; Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium ; IQ4U Consultants Ltd, London, England ; Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy ; Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria ; Univ Naples 2, Rome, Italy ; CNR, IFT, Rome, Italy ; Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy ; Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain ; Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France ; Nova Southeastern Univ, Ft Lauderdale, FL USA ; Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France ; Univ Versailles St Quentin, Suresnes, France ; Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France ; Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France ; Univ Palermo, Di Bi MIS, Palermo, Italy ; Kings Coll London, Guys & St Thomas NHS Trust, London, England ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England ; Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland ; Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy ; Kings Coll London, Allergy Acad, London, England ; Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands ; Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina ; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland ; Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark ; Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium ; Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark ; UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France ; Hosp Sirio Libanes, Sao Paulo, Brazil ; Univ Hosp Montpellier, Montpellier, France ; UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France ; Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany ; German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands ; Med Univ Lodz, Lodz, Poland ; ARIA, Mexico City, DF, Mexico ; Hosp Med Sur, AAAAI, Mexico City, DF, Mexico ; Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark ; Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark ; Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark ; Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany ; Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark ; Klinikum Univ Koln AoR, IMSIE, Cologne, Germany ; Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain ; Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece ; Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ; ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy ; Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany ; Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany ; Ctr Rhinol & Allergol, Wiesbaden, Germany ; Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland ; RiRL, Cambridge, England ; Optimum Patient Care Ltd, Singapore, Singapore ; Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain ; Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; Royal Natl Throat Nose & Ear Hosp, London, England ; UCL, London, England ; Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland ; Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England ; MRC, London, England ; Asthma UK Ctr Allerg Mechanisms Asthma, London, England ; Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland ; SLAAI, Asuncion, Paraguay ; Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil ; Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria ; Allergy Outpatient Clin Reumannplatz, Vienna, Austria ; Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain ; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands ; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands ; Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy ; Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain ; Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria ; Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany ; European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France ; INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France ; Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France ; CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France ; Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil ; Web of Science

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. ; Peer reviewed

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Santé). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified AR as mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIA World Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children.

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. In its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.)

Allergic rhinitis (AR) and asthma represent global health problems for all age groups. Asthma and rhinitis frequently coexist in the same subjects. Allergic Rhinitis and its Impact on Asthma (ARIA) was initiated during a World Health Organization workshop in 1999 (published in 2001). ARIA has reclassified ARas mild/moderate-severe and intermittent/persistent. This classification closely reflects patients' needs and underlines the close relationship between rhinitis and asthma. Patients, clinicians, and other health care professionals are confronted with various treatment choices for the management of AR. This contributes to considerable variation in clinical practice, and worldwide, patients, clinicians, and other health care professionals are faced with uncertainty about the relative merits and downsides of the various treatment options. in its 2010 Revision, ARIA developed clinical practice guidelines for the management of AR and asthma comorbidities based on the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) system. ARIA is disseminated and implemented in more than 50 countries of the world. Ten years after the publication of the ARIAWorld Health Organization workshop report, it is important to make a summary of its achievements and identify the still unmet clinical, research, and implementation needs to strengthen the 2011 European Union Priority on allergy and asthma in children. (J Allergy Clin Immunol 2012;130:1049-62.) ; Stallergenes ; ALK-Abello ; European Academy of Allergy and Clinical Immunology (EAACI) ; MSD ; Novartis ; Nycomed/Takeda ; PHADIA/Thermo Fischer ; 3M ; AstraZeneca ; GlaxoSmithKline ; Merck Frosst ; Altair ; Amgen ; Asmacure ; Boehringer-Ingelheim ; Genentech ; Pharmaxis ; Schering ; Wyeth ; Ache ; Brazilian Research Council ; Fundacao de Amparo a Pesquisa da Bahia ; Fundacao Ciencia e Tecnologia ; Sociedade Portuguesa de Alergologia e Immunologia Clinica ; Abdi Ibrahim ; OrionPharma ; Nasonebs ; Merck ; McNeal ; Chiesi ; Nycomed ; Air Liquid Healthcare ; Mundipharma ; Almirall ; Kyorin ; Teva ; UK National Health Service ; Aerocrine ; AKL Ltd ; PREDICTA ; Swiss National Science Foundation ; MeDALL ; Global Allergy and Asthma European Network (GA 2LEN) ; Christine Kuthe Center for Allergy Research and Education ; Faes Farma ; Bial ; Johnson Johnson ; Sanofi ; HAD treasurer ; Innovative Medicine Initiative (EU) ; Helse Sor-Ost RHF (Southern and Eastern Norway Regional Health Authority) ; MEDA ; Alcon ; ISTA ; Thermo-Fisher ; Airsonett ; Medical Research Council ; Moulton Charitable Trust ; AB Science ; Canadian Institutes for Health Research ; AllerGen NCE ; Merck/Schering-Plough ; Circassia ; University Hospital ; Medical School of Universidad Autonoma de Nuevo Leon, Mexico ; Children's Research Foundation (Ireland) ; Danone ; Food Standards Agency (United Kingdom) ; European Union (EU) ; DTG ; Netherlands Asthma Foundation ; Merck-Sharp-Dohme, Mexico ; Allerquim Mexico ; Abbott ; Apotex ; HRA ; MedImmune ; Schering-Plough ; Proctor Gamble ; Sunovion (Sepracor) ; Phadia ; Servier ; CSC JohnsonJohnson ; Oxygen Plus ; New Medics ; European Respiratory Society ; Societe de Pneumologie de Langue Francaise Asthma ; Ministry of Health, Welfare, and Labor ; Altana ; Takeda ; UCB ; Uriach advisory board ; NAPP ; Royal College of GPs Clinical Champion in Allergy ; Agency for Healthcare Research and Quality (AHRQ) ; AnseII ; Bayer Schering ; OST ; Fujisawa ; IHAL ; Henkel ; Kryolan ; Leti ; MSO ; Procter and Gamble ; Sanofi-Aventis ; Scientific Advisory Board for the German Society for Allergy and Clinical Immunology ; German Federal Ministry of Consumer Protection ; European Centre for Allergy Research Foundation (ECARF) ; Hop Arnaud Villeneuve, Dept Resp Dis, Univ Hosp, Montpellier, France ; INSERM, U1018, CESP Ctr Res Epidemiol & Populat Hlth, Resp & Environm Epidemiol Team, Villejuif, France ; McMaster Univ, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada ; Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland ; Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, U657, Montpellier, France ; Catholic Univ, Fac Med, Res Ctr Resp Med CIMER, Cordoba, Argentina ; Univ Genoa, Sch Specializat, Genoa, Italy ; Univ Ghent, Dept Otorhinolaryngol, Upper Airways Res Lab, B-9000 Ghent, Belgium ; CNR, Inst Translat Pharmacol, Rome, Italy ; Univ Naples 2, Naples, Italy ; Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada ; Univ Genoa, Dept Internal Med, DIMI, I-16126 Genoa, Italy ; Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68178 USA ; Univ Fed Bahia, ProAR Nucleo Excelencia Asma, Salvador, BA, Brazil ; CNPq, Salvador, BA, Brazil ; Univ Amsterdam, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands ; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands ; Univ Porto, Sch Med, Dept Hlth Informat & Decis Sci, P-4100 Oporto, Portugal ; Univ Porto, Sch Med, CINTESIS, P-4100 Oporto, Portugal ; Hosp S Joao & Inst, Dept Allergy, Oporto, Portugal ; Hosp CUF Porto, Oporto, Portugal ; Erasmus MC, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands ; Univ Washington, Sch Med, Seattle, WA USA ; Helsinki Univ Hosp, Dept Allergy, Skin & Allergy Hosp, Helsinki, Finland ; GARD ARIA Coordinator, Geneva, Switzerland ; Med Univ Lodz, Dept Internal Med Asthma & Allergy, Barlicki Univ Hosp, Lodz, Poland ; Univ S Florida, Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33612 USA ; James A Haley Vet Hosp, Tampa, FL USA ; Univ Oslo, Oslo Univ Hosp, Dept Paediat, Oslo, Norway ; CIBERES, IDIBAPS, Hosp Clin, Rhinol Unit,ENT Dept, Barcelona, Spain ; CIBERES, IDIBAPS, Hosp Clin, Smell Clin,ENT Dept, Barcelona, Spain ; Univ Chicago, Dept Otolaryngol Head & Neck Surg, Chicago, IL 60637 USA ; Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia ; Monash Univ, Melbourne, Vic 3004, Australia ; Teikyo Univ, Sch Med, Dept Med, Div Resp Med & Allergol, Tokyo 173, Japan ; EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium ; Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece ; Nippon Med Sch, Bunkyo Ku, Tokyo 113, Japan ; Univ Aberdeen, Dept Primary Care Resp Med, Aberdeen, Scotland ; Woodbrook Med Ctr, Loughborough, Leics, England ; Univ Edinburgh, Edinburgh, Midlothian, Scotland ; Univ Manitoba, Fac Med, Winnipeg, MB, Canada ; NIAID, Bethesda, MD 20892 USA ; Univ N Carolina, Sch Pharm, Chapel Hill, NC USA ; Celal Bayar Univ, Sch Med, Dept Pulmonol, Manisa, Turkey ; Allergy & Asthma Inst, Islamabad, Pakistan ; Med Univ Graz, Dept Dermatol, Graz, Austria ; Showa Univ, Sch Med, Div Allergol & Resp Med, Tokyo 142, Japan ; Transylvania Univ, Fac Med, Brasov, Romania ; Int Union TB & Lung Dis Union, Paris, France ; Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland ; Minist Hlth, Publ Hosp Med Serv, Antananarivo, Madagascar ; INSERM, EPAR U707, Paris, France ; Univ Paris 06, EPAR, UMR S, Paris, France ; Hosp Quiron Bizkaia, Dept Allergy & Immunol, Erandio Bilbao, Spain ; Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa ; WHO, Collaborating Ctr Asthma & Rhinitis, Montpellier, France ; Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Modena, Italy ; Ctr Hosp Univ Rabta, Serv Pneumol Allergol, Tunis, Tunisia ; Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands ; Hop Mami, Ariana, Tunisia ; Bangladesh Lung Fdn, Dhaka, Bangladesh ; Natl Inst Dis Chest & Hosp, Dhaka, Bangladesh ; Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany ; Univ Med Ctr, Dept Dermatol & Allergy, Bonn, Germany ; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark ; Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark ; Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA ; Univ Verona, Dept Paediat, I-37100 Verona, Italy ; Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada ; Hop Malbaie, La Malbaie, PQ, Canada ; Univ Leicester, Inst Lung Hlth, Leicester LE1 7RH, Leics, England ; Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England ; Ctr Med Docente La Trinidad Caracas, Dept Immunol, Caracas, Venezuela ; Univ Austral Chile, Fac Med, Dept Pediat, Valdivia, Chile ; Univ Fed Sao Joao del Rei, Hlth Sci Ctr, Hlth Sci Postgrad Program, Divinopolis, Brazil ; Univ Cartagena, Immunol Res Inst, Cartagena de Indias, Colombia ; So Calif Res, Mission Viejo, CA USA ; Metropolitan Univ Barranquilla, Allergy & Immunol Lab, Barranquilla, Colombia ; IRCCS San Raffaele Pisana, Rome, Italy ; Univ Cattolica Sacro Cuore, Dept Thorac Surg, Rome, Italy ; Leiden Univ, Med Ctr, Dept Publ Hlth & Primary Care, Leiden, Netherlands ; Capital Inst Pediat, Asthma Clin, Natl Cooperat Grp Pediat Res Asthma, Beijing, Peoples R China ; Capital Inst Pediat, Educ Ctr, Beijing, Peoples R China ; Ctr Asthma Res & Educ, Beijing, Peoples R China ; Hop Arnaud Villeneuve, Univ Hosp, Allergy Unit, Montpellier, France ; Univ Hosp, Dept Allergol, Sch Med CEU San Pablo Madrid, Madrid, Spain ; Georgian Natl Univ, AIETI Med Sch, SEU Clin, Med Ctr, Tbilisi, Rep of Georgia ; Univ Genoa, Dept Internal Med, IRCCS Azienda Osped Univ San Martino, I-16126 Genoa, Italy ; Univ Montpellier I, Primary Care Dept, Montpellier, France ; Nova SE Univ, Coll Osteopath Med, Davie, FL USA ; Univ Manchester, Manchester, Lancs, England ; Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark ; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Munich, Germany ; TUM, Div Environm Dermatol, Munich, Germany ; TUM, Allergy Helmholtz Ctr, Munich, Germany ; Univ Hosp Strasbourg, Chest Dis Dept, Div Pulmonol Asthma & Allergol, Strasbourg, France ; Univ Med & Pharm Iuliu Hatieganu, Dept Allergy, Med Clin 3, Romanian Soc Allergy & Clin Immunol, Cluj Napoca, Romania ; McMaster Univ, AllerGen NCE, Dept Med, Hamilton, ON, Canada ; McMaster Univ, AllerGen NCE, Michael G DeGroote Sch Med, Div Clin Immunol & Allergy,Fac Hlth Sci, Hamilton, ON, Canada ; Univ Versailles St Quentin, Hop Foch, UPRES EA 220, Suresnes, France ; Ctr Hosp Reg Annecy, Serv Pneumol, Annecy, France ; Univ Ss Cyril & Methodius, Univ Clin Pulmonol & Allergy, Skopje, Macedonia ; Georgia Hlth Sci Univ, Augusta, GA USA ; Ctr Hosp Univ Beni Messous, Serv Pneumoallergol, Algiers, Algeria ; Vilnius Univ, Fac Med, Collaborating Ctr GA2LEN, Vilnius, Lithuania ; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England ; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA ; Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt ; Egyptian Soc Pediat Allergy & Immunol, Cairo, Egypt ; Soc Marocaine Malad Resp, Casablanca, Morocco ; Ctr Resp Dis & Allergy, Casablanca, Morocco ; Vilnius Univ, Fac Med, Vilnius, Lithuania ; Univ Milan, Sch Med, Melloni Hosp, Milan, Italy ; Educ Hlth, Warwick, England ; Dokkyo Med Univ, Mibu, Tochigi, Japan ; WHO, Country Off Georgia, Tbilisi, Rep of Georgia ; Clin Ricardo Palma, Lima, Peru ; Univ Nuevo Leon UANL, Hosp Univ, Fac Med, Monterrey, Mexico ; Ctr Allergy & Immunol, Tbilisi, Rep of Georgia ; Clin Hosp Univ Chile, Dept Med, Immunol & Allergol Div, Santiago, Chile ; Univ Hosp Leuven, Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium ; Cent Reg Denmark, Ctr Publ Hlth & Qual Improvement, Aarhus, Denmark ; Allergy Ctr Vienna W, Vienna, Austria ; Natl Univ Ireland Univ Coll Cork, Dept Paediat & Child Hlth, Cork, Ireland ; Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England ; Univ Paris 11, Serv Pneumol, Hop Antoine Beclere, AP HP,INSERM,U999, Clamart, France ; Salvador Univ, Sch Med, Dept Immunol, Buenos Aires, DF, Argentina ; Univ St Andrews, St Andrews, Fife, Scotland ; Univ Paris, APHP, Ctr Asthme & Allergies, Grp Hosp Trousseau La Roche Guyon, F-75252 Paris, France ; Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, Ankara, Turkey ; George Washington Univ, Sch Med, Washington, DC USA ; Inst Asthma & Allergy, Chevy Chase, MD USA ; Hacettepe Univ Hosp, Dept Chest Dis, Adult Allergy Unit, Ankara, Turkey ; Charite, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany ; McMaster Univ, Hamilton, ON, Canada ; Hotel Dieu France, Serv Pneumol & Reanimat Med, Beirut, Lebanon ; Univ St Joseph, Fac Med, Beirut, Lebanon ; Natl Med Ctr, Seoul, South Korea ; Seoul Natl Univ, Seoul, South Korea ; Korea Asthma Allergy Fdn, Seoul, South Korea ; Ctr Hosp Univ, Serv Malad Resp, Abidjan, Cote Ivoire ; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Beatrix Childrens Hosp,Dept Pediat Pulmonol & Ped, Groningen, Netherlands ; Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland ; Karolinska Inst, Dept Clin Sci & Educ, Stockholm, Sweden ; Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden ; Vilnius Univ, Ctr Pulmonol & Allergol, Vilnius, Lithuania ; Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania ; Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico ; Univ Med & Pharm, Thanh Pho Ho Chi Minh, Vietnam ; Hop Sacre Coeur Montreal, Montreal, PQ, Canada ; Univ Montreal, Montreal, PQ, Canada ; Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China ; Univ Tennessee, Coll Med, Memphis, TN USA ; Univ Dundee, Ninewells Hosp, Asthma & Allergy Res Grp, Dundee, Scotland ; Dubai Hlth Author, Sharjah, U Arab Emirates ; Univ Sharjah, Sharjah, U Arab Emirates ; Univ Mississippi, Med Ctr, Div Clin Immunol & Allergy, Jackson, MS 39216 USA ; Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA ; Univ Arizona, Inst BIO5, Tucson, AZ USA ; Shahid Beheshti Univ Med Sci, NRITLD, Tehran, Iran ; Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Tehran, Iran ; Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany ; Maputo Cent Hosp, Dept Peadiat, Maputo, Mozambique ; Eduardo Mondlane Univ, Fac Med, Maputo, Mozambique ; Childrens Hosp La Fe, Unit Pediat Allergy & Pneumol, Valencia, Spain ; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden ; Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden ; Univ Calif San Diego, Allergy & Asthma Med Grp, San Diego, CA 92103 USA ; Univ Calif San Diego, Res Ctr, San Diego, CA 92103 USA ; IMSS, Dept Allergy & Clin Immunol, Ctr Med Nacl Siglo 21, Mexico City, DF, Mexico ; Univ Aachen, Dept Dermatol, Aachen, Germany ; Inst Pneumol Marius Nasta, Bucharest, Romania ; Tishreen Univ, Sch Med, Dept Internal Med, WHO EMRO Collaborating Ctr Training & Res Chron R, Latakia, Syria ; CUF Descobertas Hosp, Immunoallergy Dept, Lisbon, Portugal ; Univ Padua, Dept Pediat, Food Allergy Referral Ctr Veneto Reg, Padua, Italy ; Mustapha Hosp, Algiers, Algeria ; Sci Ctr Childrens Hlth RAMS, Moscow, Russia ; Hosp Hospitaller Bros Buda, Budapest, Hungary ; Charite, Allergie Ctr Charite ECARF, Dept Dermatol Venerol & Allergy, D-13353 Berlin, Germany ; German Red Cross Hosp Westend, Berlin, Germany ; Jagiellonian Univ, Sch Med, Dept Pulmonol, Krakow, Poland ; Kinshasa Univ, ENT Dept, Kinshasa, Zaire ; Chiba Univ Hosp, Dept Otorhinolaryngol, Chiba, Japan ; Nippon Med Sch, Dept Otolaryngol, Bunkyo Ku, Tokyo 113, Japan ; Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso ; Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey ; Mem Hlth Grp, Istanbul, Turkey ; Charles Univ Prague, Fac Med Plzen, Dept Immunol & Allergol, Prague, Czech Republic ; MESSERLI Res Inst, Vienna, Austria ; Med Univ Vienna, Univ Vet Med Vienna, Vienna, Austria ; Univ Vienna, Vienna, Austria ; Ajou Univ, Sch Med, Suwon 441749, South Korea ; NICE, Paris, France ; Soc Pneumol Langue Francaise, Paris, France ; Krankenhaus Hietzing, Karl Landsteiner Inst Expt & Clin Pneumol, Dept Pulm Med, Vienna, Austria ; Alexanders Univ Hosp, Clin Allergy & Asthma, Sofia, Bulgaria ; Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pulmonol, Groningen, Netherlands ; Univ Cape Town, Lung Inst, ZA-7925 Cape Town, South Africa ; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa ; Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands ; Grosshansdorf Clin, Grosshansdorf, Germany ; Hop Prive Athis Mons, Serv Pneumol, Athis Mons, France ; Helsinki Univ Hosp, Dept Dermatol, Skin & Allergy Hosp, Helsinki, Finland ; Tech Univ Munich, CKCARE, Dept Dermatol Allergy Biederstein, Munich, Germany ; Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA ; Med Univ Silesia, Dept & Clin Internal Dis Allergol & Clin Immunol, Katowice, Poland ; Complesso Integrato Columbus, Allergy Unit, Rome, Italy ; IRCCS Oasi Maria SS, Troina, Italy ; Son Pisa Primary Care Ctr, IB Salut Balear Hlth Serv, Int Primary Care Resp Grp, Palma de Mallorca, Spain ; Hosp Luz, Immunoallergy Dept, Lisbon, Portugal ; Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA ; Childrens Mercy Hosp, Kansas City, MO USA ; Emek Med Ctr, Afula, Israel ; Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel ; Ctr Med Docente La Trinidad, Dept Allergy & Clin Immunol, Caracas, Venezuela ; UCL, Royal Natl TNE Hosp, London, England ; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland ; Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh, Midlothian, Scotland ; Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil ; Natl Ctr Cardiol & Internal Med, Bishkek, Kyrgyzstan ; Ctr ACI Immunoflow, Czech Initiat Asthma, Prague, Czech Republic ; GAAPP, Vienna, Austria ; Ctr Res Environm Epidemiol CREAL, Barcelona, Spain ; Pontificia Univ Catolica RGS, Sch Med, Porto Alegre, RS, Brazil ; Univ Nevada, Sch Med, Reno, NV 89557 USA ; Hosp Mar, Municipal Inst Med Res IMIM, Barcelona, Spain ; CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain ; Univ Pompeu Fabra UPF, Barcelona, Spain ; Jagiellonian Univ, Coll Med, Krakow, Poland ; Coimbra Univ Hosp, Immunoallergy Dept, Coimbra, Portugal ; Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA ; Finnish Inst Occupat Hlth, Helsinki, Finland ; Univ Laval, Fac Med, Dept Obstet & Gynecol, Laval, PQ, Canada ; Med Univ Vienna, Christian Doppler Lab Allergy Res, Div Immunopathol, Dept Pathophysiol & Allergy Res,Ctr Pathophysiol, Vienna, Austria ; Hosp Clin Barcelona, Dept Pneumol, Allergy Unit, Immunoallergia Resp Clin, Barcelona, Spain ; IDIBAPS, Barcelona, Spain ; CIBERES, Barcelona, Spain ; Univ Paris 13, Bobigny, France ; Avicenne Hosp, AP HP, Bobigny, France ; Vilnius Univ, Fac Med, Dept Paediat, Vilnius, Lithuania ; Lithuanian Natl Council Childs Hlth, Vilnius, Lithuania ; Terveystalo Turku, Allergy Clin, Turku, Finland ; Univ Turku, Dept Lung Dis & Clin Immunol, Turku, Finland ; Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium ; Catholic Univ Louvain, Univ Hosp Mt Godinne, Yvoir, Belgium ; Radboud Univ Nijmegen, Med Ctr, Dept Primary & Community Care, NL-6525 ED Nijmegen, Netherlands ; Siriraj Hosp, Fac Med, Dept Pediat, Bangkok, Thailand ; CNR, IBIM, Palermo, Italy ; Clin Physiol IFC, Pisa, Italy ; Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore ; Floridsdorf Allergy Ctr FAZ, Vienna, Austria ; Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria ; Bradford Teaching Hosp Fdn Trust, Bradford Inst Hlth Res, Bradford, W Yorkshire, England ; Olmsted Med Ctr, Dept Res, Rochester, MN USA ; Univ Minnesota, Dept Family & Community Hlth, Rochester, MN USA ; Harvard Univ, Sch Publ Hlth, Cyprus Int Inst Environm & Publ Hlth Assoc, Limassol, Cyprus ; Cyprus Univ Technol, Limassol, Cyprus ; Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, ZA-7925 Cape Town, South Africa ; Catholic Univ Cordoba, Sch Med, Dept Otorhinolaryngol, Cordoba, Argentina ; Guangzhou Med Univ, Guangzhou Inst Resp Dis, Guangzhou, Guangdong, Peoples R China ; Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China ; Univ Clin Resp & Allerg Dis, Golnik, Slovenia ; Charite, Network Excellence, Global Allergy & Asthma European Network GA2LEN, D-13353 Berlin, Germany ; Universidade Federal de São Paulo, Dept Pediat, Div Allergy Clin Immunol & Rheumatol, São Paulo, Brazil ; Web of Science